AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 42 min read$IRTC

Smith Mervin sold $75K of IRTC

Smith Mervin (EVP Strategic Business Ops) sold 617 shares of iRhythm Holdings, Inc. (IRTC) at $122.12 on 2026-08-03.

Original reporting
SEC EDGAR · Smith Mervin
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
high confidence
Mentioned
$IRTC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The only new fact is the insider sale details (shares, price, total value, post-transaction holdings). There is no accompanying company-specific catalyst such as guidance, contract, or regulatory action.

02

Market read

Traders may note insider selling, but the disclosed transaction is small and lacks fundamental implications.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it does not provide intent, tax context, or whether other insiders are selling/buying around the same period.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-04, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralHigh confidence
Context

iRhythm Holdings Form 4 shows EVP Strategic Business Ops Smith Mervin sold 617 shares on 2026-08-03 for about $75.3K.

Expected impact

Low near-term impact; any price reaction would be more sentiment-driven than fundamentals-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, deal, or regulatory event. The transaction value (~$75K) is modest relative to typical company market caps, and the article provides no new operational or financial information.

Market effects

Sector

No clear sector read-through from a single small insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Smith Mervin

    EVP Strategic Business Ops who sold 617 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min